ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 636

Neutrophil-Mediated Interferon Activation In Systemic Lupus Erythematosus Bone Marrow

Anna Bird1, Nida Meednu2, Javier Rangel-Moreno3, Srilakshmi Yalavarthi4, Jennifer Barnard1, Teresa Owen5, Jason S. Knight6, Alfred Rabinovich1, Arumugam Palanichamy2, Jane Liesveld7, Jason W Bauer8, Emily Baechler9, Mariana J. Kaplan10 and Jennifer H. Anolik11, 1Medicine-Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 2Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 3Medicine- Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, 4University of Michigan Rheumatology, Ann Arbor, MI, 5Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, 6Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, 7Hematology/Oncology, University of Rochester Medical Center, Rochester, NY, 8University of Minnesota, Minneapolis, MN, 9Medicine, University of Minnesota, Minneapolis, MN, 10Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD, 11Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: B cells, Bone marrow, interferons and neutrophils, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Mechanisms and Biomarkers

Session Type: Abstract Submissions (ACR)

Background/Purpose: Although SLE is known to be associated with a type I interferon signature in the peripheral blood, the precise site and mechanism of IFN pathway activation in SLE remain unclear. Given that IFN can impair B cell development in murine bone marrow (BM), we asked whether IFN activation is present in SLE BM and its potential consequences for disease pathogenesis.

Methods: The IFN signature was assessed in BM of SLE patients (n=28) and normal controls (NC, n=20) by examining the relative expression of 3 IFN inducible genes IFIT1, IRF7, and G1P2 by qPCR. Neutrophils were isolated using Percoll density gradient and phenotype confirmed by flow cytometry. Type I IFN, BAFF, and APRIL expression in total aspirates and purified neutrophils was measured by qPCR normalized to GAPDH. Neutrophil expression of BAFF and APRIL was confirmed by immunofluorescence. NZM2328 lupus prone female mice (pre-disease 12 wk) were compared to Balb/c (n=7 per group) for Type I IFN activation and production and secretion of cytokines that may alter B cell development. B cells were defined by flow cytometry using standard markers.

Results: The majority of SLE patients (57%) had an IFN signature in the BM that was more pronounced than the paired peripheral blood (PB) and associated with both higher autoantibodies and disease activity (BM vs. PB for IFN high group compared to NC: 45.7-fold vs. 18.5-fold, p=0.0009 for G1P2; 108.5-fold vs. 54-fold, p=0.005 for IFIT1). There was also a significantly higher expression of BAFF and APRIL in the IFN high SLE BM aspirates (BAFF: 2.45+/-0.66 fold compared to NC; APRIL: 6.04+/-2.5, p=0.01). BM neutrophils in SLE showed a significantly higher expression of APRIL and IFNα when compared to NC BM (p=0.04) and also a correlation between IFNα expression and APRIL (p=0.0004) and BAFF expression (p=0.0001), suggesting that IFNa may be driving APRIL and BAFF. SLE IFN high patients had profound alterations in the BM B cell compartment with significant reductions in precursor B cells (p=0.02) but increases in transitional B cells (27%, 4.6%, and 7.5% T1/T2 in IFN high SLE, IFN low SLE and NC, respectively; p=0.013). Lupus prone mice had similar alterations in B cell development. Notably, BM neutrophils from lupus mice displayed significant up-regulation of Mx-1 (10-fold, p=0.01), as well as increases in IFNα, IFNb, and BAFF (p=0.03, 0.03, 0.04). In bone sections, we also detected numerous Gr-1+MPO+ neutrophils in NZM mice expressing APRIL and BAFF in close contact with B220+ B cells.  

Conclusion: Overall, our results highlight the importance of the BM as a target organ in SLE and provide a previously unappreciated connection between IFN activation, neutrophils, and B cell selection.

This work was supported in part by grants R01 AI077674 (JA), P01 AI078907 (JA), U19 AI56390 Autoimmunity Center of Excellence (JA), R01 HL088419 (MJK), and a Rheumatology Research Foundation Rheumatology Scientist Development Award (JSK).


Disclosure:

A. Bird,
None;

N. Meednu,
None;

J. Rangel-Moreno,
None;

S. Yalavarthi,
None;

J. Barnard,
None;

T. Owen,
None;

J. S. Knight,
None;

A. Rabinovich,
None;

A. Palanichamy,
None;

J. Liesveld,
None;

J. W. Bauer,

UCB,

3;

E. Baechler,
None;

M. J. Kaplan,
None;

J. H. Anolik,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/neutrophil-mediated-interferon-activation-in-systemic-lupus-erythematosus-bone-marrow/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology